A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors. (2019)
Attributed to:
Using MHC class I peptides to modulate NK cell activity, as a basis for immunotherapy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.33969
Publication URI: https://www.repository.cam.ac.uk/handle/1810/286657
Type: Journal Article/Review